Re-Starting a Company, Keeping Hope Alive: Chip Clark on The Long Run

Today’s guest on The Long Run is Chip Clark.

Chip Clark, CEO, Genocea 

He’s the CEO of Cambridge, Mass.-based Genocea Biosciences. This vaccine platform company got into a jam last summer. It completed a Phase II trial with its lead therapeutic vaccine for genital herpes. Clark tried to insist the trial was a success and the product had a future. The market disagreed. The stock tanked. Cash ran low. Morale ebbed.

Something had to be done.

How did Clark think about re-starting the company – pivoting, as he says – toward a new future as a personalized neoantigen cancer vaccine developer? Clark was pretty candid about this difficult stretch at Genocea, and I think many entrepreneurs will be able to relate to the experience and learn from it.

You may also like

Better Cancer Treatment Through Better Information: Cindy Perettie on The Long Run
Cancer Survivor and Cancer Drug Developer: Laura Shawver on The Long Run
Predicting Who Will Benefit from Cancer Drugs: Liz O’Day on The Long Run
From Open Biology to Pharma Leadership: Jay Bradner of Novartis on The Long Run